Developer docs
API playgroundTry for free, no card

Search company profiles

TrialJectory

Full company profile

uuid02lp7dn

Namestring
TrialJectory
Company typeenum
Private
Founded yearstring
-
Descriptiontext

TrialJectory, doing business as Leal Health, operates an AI-powered decision support platform that helps cancer patients identify personalized treatment options and clinical trials. The patient experience is fully self-serve: users select their cancer type, complete a 2-minute questionnaire, and receive an instantly generated, shareable list of treatments matched to their specific diagnosis. The matching engine is supplemented by a dedicated human support team of PhDs, MDs, Nurses, and Social Workers who spend approximately four hours per patient on education and advocacy. To date the platform reports over 3,125,000 treatment matches completed.

The product surface expanded in 2023 with an oncologist-facing module that delivers personalized clinical trial matches to providers, positioning the company for B2B monetization alongside the free patient-facing tool. Distribution is direct-to-consumer via leal.health and amplified through 22+ partnerships with patient advocacy organizations including the American Cancer Society, Colorectal Cancer Alliance, Tempus, MPN Research Foundation, NCCN, Sharsheret, Breast Cancer Alliance, and The Jackson Laboratory's Maine Cancer Genomics Initiative. The decision support service holds FDA approval, and the company has earned external recognition including Time Magazine Best Inventions (2020), Fast Company World Changing Ideas (2021), and Business Insider Most Promising Healthcare Startups (2023).

Revenue mechanics are not publicly disclosed. The patient-facing service is free, and the input material indicates no pricing model, contract structure, paying customer logos, funding rounds, headcount, ownership, or management team information. This represents a significant analytical gap. Available evidence suggests B2B monetization through pharma, payer, or health system relationships is the most likely revenue vector, but no commercial terms are confirmed.

Short descriptiontext

Leal Health (formerly TrialJectory) operates an AI-powered decision support platform that matches cancer patients with personalized treatment options and clinical trials. The free, direct-to-consumer service reports over 3.1 million treatment matches and integrates with 22+ patient advocacy organizations and clinical partners.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical trial matching, cancer treatment platform, patient decision support, oncology treatment matching, AI healthcare platform
Industry1 code
PRIMARYHLACAGAC
Order Sets, Care Plans & Clinical Pathways (CPOE-integrated)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
NAICS code1 code
  • Management Consulting Services54161
SIC code2 codes
  • Services-Health Services8000
  • Services-Prepackaged Software7372
Product category
Cancer Treatment Decision Support
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Patient-facing service
TypeFreemium
Description

The platform is offered free to patients. Revenue model is not explicitly disclosed in available source material. The company positions itself as democratizing access to cancer treatment without pharma bias, suggesting potential partnerships with healthcare systems, pharmaceutical companies, or payers rather than direct patient charges.

leal.health
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
Pricing details1 tier
1Free for patients
ModelFreemiumBilling cadencePay-as-you-go
Notes

All features are provided free of charge to cancer patients including the 2-minute questionnaire, instant AI-powered treatment matching, and dedicated patient support team access.

leal.health
GTM typeB2C
B2C
Offering typeSoftware
Software
Core offering1 text field

TrialJectory (doing business as Leal Health) operates an AI-powered cancer treatment decision support platform that enables patients to receive personalized treatment recommendations. Patients select their cancer type, complete a 2-minute questionnaire, and instantly receive a shareable personalized list of cutting-edge treatments and clinical trials matched to their exact diagnosis. The platform is FDA-approved, provided free of charge to patients, and is supported by a dedicated clinical team of PhDs, MDs, Nurses, and Social Workers averaging 4 hours of support per patient.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 3,125,000 treatment matches made for patients
+2 more records
Product overview1 text field

Leal Health operates as a single unified AI-powered platform focused on democratizing access to advanced cancer treatment. The core offering is an AI-driven decision support platform that processes patient diagnosis information through a questionnaire-based intake system and instantly generates personalized, shareable lists of cutting-edge cancer treatments matched to each patient's exact condition. The platform combines AI-powered instant matching technology with dedicated human support from a team of PhDs, MDs, Nurses, and Social Workers who provide educational support to patients.

Product and service1 record
1AI-Powered Cancer Treatment Decision Support Platform
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1American Cancer Society
Strategic tierCoreTypeGTM or Marketing Partner
Description

Major cancer advocacy organization partnership to direct patients to the platform for unbiased treatment matching

leal.health
2Tempus
Strategic tierCoreTypeTechnology or Integration
Description

Life sciences clinical trial solutions partnership for matching patients with clinical trials

leal.health
Strategic tierCoreTypeGTM or Marketing Partner
Description

Patient support organization partnership providing clinical trial finder capabilities for colorectal cancer patients

4MPN Research Foundation
Strategic tierMinorTypeGTM or Marketing Partner
Description

MPN clinical trials partnership directing myeloproliferative neoplasm patients to the platform

leal.health
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Announced collaboration to provide cancer patients with access to expert medical perspectives and treatment matching

Strategic tierMinorTypeGTM or Marketing Partner
Description

Breast cancer support organization directing patients to treatment matching services

Strategic tierMinorTypeGTM or Marketing Partner
Description

Breast cancer advocacy organization partnership for patient referrals

Strategic tierMinorTypeGTM or Marketing Partner
Description

Patient resources partnership providing support group referrals to patients

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Syapse focuses on real-world evidence in oncology, partnering with health systems and pharma. While more focused on provider-side data aggregation than patient-facing matching, they compete for similar oncology AI/data budgets from pharma customers.

2Tempus
TypeDirect peer
Description

Tempus is a technology company focused on precision medicine through AI and data analytics. While Tempus serves both clinical trial matching and broader genomic profiling, they are Leal's explicit integration partner for clinical trial solutions, making them the closest comparable in AI-driven oncology decision support infrastructure.

TypeBroad incumbent
Description

Flatiron Health (Roche subsidiary) provides oncology-specific EHR, real-world evidence, and clinical trial solutions. They are a broader incumbent in oncology data and trial matching with established pharma relationships that pose competitive and partnership opportunities for Leal.

TypeBroad incumbent
Description

IQVIA is a global leader in clinical research services, real-world evidence, and healthcare data analytics. While operating at vastly larger scale across all therapeutic areas, they directly compete for pharma clinical trial recruitment budgets and could acquire or replicate Leal's capabilities.

5Deep 6 AI
TypeDirect peer
Description

Deep 6 AI uses AI and natural language processing to match patients to clinical trials, with a focus on accelerating patient recruitment for sponsors and health systems. They directly compete with Leal for pharma clinical trial matching budgets.

TypeDirect peer
Description

Outcomes4Me is an AI-driven platform that empowers cancer patients with personalized treatment options and clinical trial matching. They share Leal's direct-to-consumer oncology patient focus and similar AI decision support value proposition.

7Mendel
TypeDirect peer
Description

Mendel applies AI to clinical trial recruitment and real-world evidence, with an enterprise focus on pharma and providers. While more enterprise-oriented than Leal, they directly compete in the AI-powered clinical trial matching space and target similar pharma customers.

TypeDirect peer
Description

Cure Forward operates a patient-facing platform for clinical trial matching and treatment options, with a similar focus on oncology patient empowerment. They compete directly for the same patient audience and pharma recruitment dollars.

TypeDirect peer
Description

Antidote is a digital health company that uses structured data and AI to match patients to clinical trials, with a strong oncology focus. They share the patient-facing clinical trial matching model and target the same pharma sponsorship revenue streams.

TypeDirect peer
Description

Massive Bio uses AI to match cancer patients with clinical trials, operating with a similar patient-facing B2C/B2B model. They directly compete with Leal in oncology clinical trial matching and treatment decision support.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TrialJectory

Cancer Treatment Decision Supporttrialjectory.com

Leal Health (formerly TrialJectory) operates an AI-powered decision support platform that matches cancer patients with personalized treatment options and clinical trials. The free, direct-to-consumer service reports over 3.1 million treatment matches and integrates with 22+ patient advocacy organizations and clinical partners.

What TrialJectory does

TrialJectory, doing business as Leal Health, operates an AI-powered decision support platform that helps cancer patients identify personalized treatment options and clinical trials. The patient experience is fully self-serve: users select their cancer type, complete a 2-minute questionnaire, and receive an instantly generated, shareable list of treatments matched to their specific diagnosis. The matching engine is supplemented by a dedicated human support team of PhDs, MDs, Nurses, and Social Workers who spend approximately four hours per patient on education and advocacy. To date the platform reports over 3,125,000 treatment matches completed.

The product surface expanded in 2023 with an oncologist-facing module that delivers personalized clinical trial matches to providers, positioning the company for B2B monetization alongside the free patient-facing tool. Distribution is direct-to-consumer via leal.health and amplified through 22+ partnerships with patient advocacy organizations including the American Cancer Society, Colorectal Cancer Alliance, Tempus, MPN Research Foundation, NCCN, Sharsheret, Breast Cancer Alliance, and The Jackson Laboratory's Maine Cancer Genomics Initiative. The decision support service holds FDA approval, and the company has earned external recognition including Time Magazine Best Inventions (2020), Fast Company World Changing Ideas (2021), and Business Insider Most Promising Healthcare Startups (2023).

Revenue mechanics are not publicly disclosed. The patient-facing service is free, and the input material indicates no pricing model, contract structure, paying customer logos, funding rounds, headcount, ownership, or management team information. This represents a significant analytical gap. Available evidence suggests B2B monetization through pharma, payer, or health system relationships is the most likely revenue vector, but no commercial terms are confirmed.

TrialJectory firmographics

Firmographics
Name
TrialJectory
Website
https://trialjectory.com
Company type
Private
Operating status
Operating
Short description
Leal Health (formerly TrialJectory) operates an AI-powered decision support platform that matches cancer patients with personalized treatment options and clinical trials. The free, direct-to-consumer service reports over 3.1 million treatment matches and integrates with 22+ patient advocacy organizations and clinical partners.
Ownership category
akta.pro rank

TrialJectory industry classification

Industry
Product category
Cancer Treatment Decision Support
NAICS
Management Consulting Services (54161)
SIC
Services-Health Services (8000), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACAGAC
Order Sets, Care Plans & Clinical Pathways (CPOE-integrated)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools

Keywords

  • Clinical trial matching
  • Cancer treatment platform
  • Patient decision support
  • Oncology treatment matching
  • AI healthcare platform

Where TrialJectory is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

TrialJectory business model

Business model
GTM type
B2C
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Patient-facing service: The platform is offered free to patients. Revenue model is not explicitly disclosed in available source material. The company positions itself as democratizing access to cancer treatment without pharma bias, suggesting potential partnerships with healthcare systems, pharmaceutical companies, or payers rather than direct patient charges.

Pricing tiers

ModelBillingPrice
FreemiumPay-as-you-goFree for patients

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

TrialJectory product offering

Product offering

Core offering

TrialJectory (doing business as Leal Health) operates an AI-powered cancer treatment decision support platform that enables patients to receive personalized treatment recommendations. Patients select their cancer type, complete a 2-minute questionnaire, and instantly receive a shareable personalized list of cutting-edge treatments and clinical trials matched to their exact diagnosis. The platform is FDA-approved, provided free of charge to patients, and is supported by a dedicated clinical team of PhDs, MDs, Nurses, and Social Workers averaging 4 hours of support per patient.

Product overview

Leal Health operates as a single unified AI-powered platform focused on democratizing access to advanced cancer treatment. The core offering is an AI-driven decision support platform that processes patient diagnosis information through a questionnaire-based intake system and instantly generates personalized, shareable lists of cutting-edge cancer treatments matched to each patient's exact condition. The platform combines AI-powered instant matching technology with dedicated human support from a team of PhDs, MDs, Nurses, and Social Workers who provide educational support to patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • AI-Powered Cancer Treatment Decision Support Platform

Quantifiable outcome

  • Over 3,125,000 treatment matches made for patients
  • +2 more outcomes

Companies that use TrialJectory

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles1 record

TrialJectory technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

TrialJectory partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • American Cancer SocietycoreGTM or Marketing PartnerMajor cancer advocacy organization partnership to direct patients to the platform for unbiased treatment matching
  • TempuscoreTechnology or IntegrationLife sciences clinical trial solutions partnership for matching patients with clinical trials
  • Colorectal Cancer AlliancecoreGTM or Marketing PartnerPatient support organization partnership providing clinical trial finder capabilities for colorectal cancer patients
  • MPN Research FoundationminorGTM or Marketing PartnerMPN clinical trials partnership directing myeloproliferative neoplasm patients to the platform
  • SummusminorStrategic or Co-development PartnerAnnounced collaboration to provide cancer patients with access to expert medical perspectives and treatment matching
  • SharsheretminorGTM or Marketing PartnerBreast cancer support organization directing patients to treatment matching services
  • Breast Cancer AllianceminorGTM or Marketing PartnerBreast cancer advocacy organization partnership for patient referrals
  • NCCN (National Comprehensive Cancer Network)minorGTM or Marketing PartnerPatient resources partnership providing support group referrals to patients

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

TrialJectory competitors and assessment

Company assessment

Broad incumbents

  • Syapse: Syapse focuses on real-world evidence in oncology, partnering with health systems and pharma. While more focused on provider-side data aggregation than patient-facing matching, they compete for similar oncology AI/data budgets from pharma customers.
  • Flatiron Health: Flatiron Health (Roche subsidiary) provides oncology-specific EHR, real-world evidence, and clinical trial solutions. They are a broader incumbent in oncology data and trial matching with established pharma relationships that pose competitive and partnership opportunities for Leal.
  • IQVIA: IQVIA is a global leader in clinical research services, real-world evidence, and healthcare data analytics. While operating at vastly larger scale across all therapeutic areas, they directly compete for pharma clinical trial recruitment budgets and could acquire or replicate Leal's capabilities.

Direct peers

  • Tempus: Tempus is a technology company focused on precision medicine through AI and data analytics. While Tempus serves both clinical trial matching and broader genomic profiling, they are Leal's explicit integration partner for clinical trial solutions, making them the closest comparable in AI-driven oncology decision support infrastructure.
  • Deep 6 AI: Deep 6 AI uses AI and natural language processing to match patients to clinical trials, with a focus on accelerating patient recruitment for sponsors and health systems. They directly compete with Leal for pharma clinical trial matching budgets.
  • Outcomes4Me: Outcomes4Me is an AI-driven platform that empowers cancer patients with personalized treatment options and clinical trial matching. They share Leal's direct-to-consumer oncology patient focus and similar AI decision support value proposition.
  • Mendel: Mendel applies AI to clinical trial recruitment and real-world evidence, with an enterprise focus on pharma and providers. While more enterprise-oriented than Leal, they directly compete in the AI-powered clinical trial matching space and target similar pharma customers.
  • Cure Forward: Cure Forward operates a patient-facing platform for clinical trial matching and treatment options, with a similar focus on oncology patient empowerment. They compete directly for the same patient audience and pharma recruitment dollars.
  • Antidote Me: Antidote is a digital health company that uses structured data and AI to match patients to clinical trials, with a strong oncology focus. They share the patient-facing clinical trial matching model and target the same pharma sponsorship revenue streams.
  • Massive Bio: Massive Bio uses AI to match cancer patients with clinical trials, operating with a similar patient-facing B2C/B2B model. They directly compete with Leal in oncology clinical trial matching and treatment decision support.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

TrialJectory financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TrialJectory leadership team

Management profile

Number of profiles

TrialJectory funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TrialJectory M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TrialJectory

What does TrialJectory do?

TrialJectory (doing business as Leal Health) operates an AI-powered cancer treatment decision support platform that enables patients to receive personalized treatment recommendations. Patients select their cancer type, complete a 2-minute questionnaire, and instantly receive a shareable personalized list of cutting-edge treatments and clinical trials matched to their exact diagnosis. The platform is FDA-approved, provided free of charge to patients, and is supported by a dedicated clinical team of PhDs, MDs, Nurses, and Social Workers averaging 4 hours of support per patient.

Is TrialJectory a public or private company?

TrialJectory is a private company. It is classified as unknown and is currently operating.

When was TrialJectory founded?

TrialJectory was founded in -1.

Where is TrialJectory based?

TrialJectory is headquartered in New York, United States, in the North America region.

How does TrialJectory make money?

One revenue line is on record: patient-facing service.

Who are TrialJectory's main competitors?

Broad incumbents on record are Syapse, Flatiron Health and IQVIA. Direct peers are Tempus, Deep 6 AI, Outcomes4Me, Mendel, Cure Forward, Antidote Me and Massive Bio.

Does TrialJectory have an API?

No public API is recorded for TrialJectory.

What industry is TrialJectory in?

TrialJectory's product category is Cancer Treatment Decision Support. Its primary akta.pro industry code is HLACAGAC, Order Sets, Care Plans & Clinical Pathways (CPOE-integrated). Its NAICS code is 54161 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNew Trialjectory Data Shows Triple-Negative Breast Cancer Patients More Likely to Seek Clinical Trial Options Prior to Treatment for Advanced DiseaseTrialjectory announced new data showing that triple-negative breast cancer patients are more likely to seek clinical trial options compared to other breast cancer subtypes, with findings presented at the 2022 San Antonio Breast Cancer Symposium. Out of nearly 10,000 breast cancer patients who signed up for Trialjectory's platform between January 2020 and December 2021, over a quarter (27%) had TNBC—more than double their prevalence in the general breast cancer population. Advanced TNBC patients initiated clinical trial searches earlier, with 34% doing so before chemotherapy compared to 22% of non-TNBC patients.BioSpaceTrialjectory Grows Pharmaceutical and Biotech Clinical Trial Partnerships by 800 PercentTrialjectory announced it is working with over 50 pharmaceutical companies, biotechs, and CROs, an 800% increase since 2020. The platform reports 10-15% patient enrollment versus 2-3% industry average, and plans to reach 100,000 patients by year-end.PR NewswireTrialjectory Grows Pharmaceutical and Biotech Clinical Trial Partnerships by 800 PercentTrialjectory, an AI-powered decision support platform for cancer clinical trials, announced it is currently working with more than 50 pharmaceutical companies, emerging biotechs, and Contract Research Organizations—a growth of 800 percent since the beginning of 2020. The company's platform matches patients to trials and reports that 10 to 15 percent of its patients enroll in clinical trials compared to the industry average of 2 to 3 percent, while reducing enrollment timelines by 20 percent and prequalification time by up to 25 percent. Trialjectory more than tripled its revenue from new pharmaceutical customers between 2020 and 2021 and, in the first half of 2022, already exceeded its total 2021 revenue.PR NewswireTrialjectory Appoints Gregory T. Simpson as Chief Marketing OfficerTrialjectory, an AI-powered decision-support platform for patients, healthcare providers, and pharmaceutical companies, has appointed Gregory T. Simpson as its Chief Marketing Officer, effective immediately. Mr. Simpson brings over two decades of marketing and technology experience, most recently serving as Senior Vice President and Head of Marketing at Saama Technologies, an AI-driven clinical cloud company. In his new role, he will lead Trialjectory's overall marketing strategy and branding initiatives as the company works to expand patient access to advanced cancer treatments.PR NewswireTrialjectory Boasts Over 54 Percent Growth in New Cancer Patient Users from Diverse Ethnic and Racial Backgrounds in Q1 2022Trialjectory, an AI-powered decision-support platform for cancer patients, announced over 54 percent growth in new cancer patient users from diverse ethnic and racial backgrounds during Q1 2022. Among the over 65,000 cancer patients on its platform, 35 percent come from underrepresented racial and ethnic backgrounds, while 75 percent live in rural communities with limited access to major metropolitan cancer centers where most clinical trials take place. The company's growth aligns with new FDA guidelines mandating that pharmaceutical companies enroll more diverse patient populations in clinical trials.PR NewswireMPN Research Foundation and Trialjectory Partner to Provide Advanced Clinical Trial Matching Services for Patients in NeedThe MPN Research Foundation and Trialjectory announced a collaboration to bring Trialjectory's AI-powered clinical trial finder to MPN patients. The tool matches patients with relevant trials and provides access to specialists, aiming to improve access to advanced treatments for rare blood cancers.PR NewswireTrialjectory Raises $20 Million to Transform the Cancer Care IndustryTrialjectory, an AI-powered decision-support platform for cancer care, announced the closing of a $20 million Series A funding round led by Insight Partners. The company intends to use this capital to expand its patient community and enhance its services for pharmaceutical partners in clinical trial design. This investment follows significant growth metrics, including an 800% year-over-year revenue increase and a user base expansion to over 50,000 members.WsjTrialjectory Collects $20 Million to Match Cancer Patients to TrialsTrialjectory Inc. has raised $20 million in new venture capital to enhance its service that uses artificial intelligence to match cancer patients with clinical trials. The company, founded by cancer survivor Tzvia Bader, aims to improve accessibility to clinical trial options for patients. This funding will support the expansion of their platform in a critical area of cancer treatment.VC News DailyTrialjectory Raises $20M in Series ATrialjectory, an AI-powered clinical trial-matching platform for cancer patients and healthcare providers, has raised $20 million in a Series A funding round led by Insight Partners, with participation from new investor JAL Ventures and existing investors Contour Venture Partners, Rho Capital, and TIA Ventures. The platform uses self-reported clinical information to facilitate clinical trial search and enrollment, partnering with patients, healthcare providers, and pharmaceutical companies to reduce operational costs and expedite drug development timelines.